MedTrace Logo

Effectiveness of Anti-IL-5/IL5R Inhibitors

NCT06239441 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 108

Last updated 2024-10-28

Study results available
· View outcomes & findings →

Summary

The goal of this observational study is to assess the response to treatment, in patients 18 years and older diagnosed with severe asthma in whom an IL5/IL5R antagonists was initiated between 2012 and 2020.

The main question\[s\] it aims to answer are:

* What is the response rate after one year of treatment with IL5/IL5R antagonists.
* What is the response and remission rate after one year of treatment with IL5/IL5R antagonists in subjects who fullfilled the original randomized control trials (RCTs) inclusion criteria compared with those who did not.

Conditions

Interventions

DRUG

IL5/IL5R Antagonists

Treatment with IL5/IL5R antagonists for one year

Sponsors & Collaborators

  • GlaxoSmithKline

    collaborator INDUSTRY

  • Centre Integre Universitaire de Sante et Services Sociaux du Nord de l'ile de Montreal

    lead OTHER

Principal Investigators

  • Catherine Lemiere, MD · Centre Integre Universitaire de Sante et Services Sociaux du Nord de l'ile de Montreal

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-02-16
Primary Completion
2023-06-13
Completion
2023-11-29

Countries

  • Canada

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06239441 on ClinicalTrials.gov